JPET approves PN6047
In collaboration with our research partners at the University of Bristol, we have had a manuscript detailing the results of our preclinical studies of PN6047 accepted for publication in the highly cited Journal of Experimental Pharmacology and Therapeutics (JPET), the official journal of the American Society for Pharmacology and Experimental Therapeutics (ASPET).
We are delighted to have this peer-reviewed validation of our candidate compound made available for the Biomedical community to read and digest and we are confident that it will reignite interest in the potential value of biased signalling delta opioid receptor agonists for the treatment of a variety of conditions including our key target of neuropathic pain and for others including migraine, anxiety and depression and chronic cough. Details of the article which will soon be available electronically in advance of the printed version are shown below:
Title: A novel G protein-biased agonist at the δ opioid receptor with analgesic efficacy in models of chronic pain.
First Author: Dr Alexandra Conibear (Research Associate, School of Physiology, Pharmacology & Neuroscience, University of Bristol) with Corresponding Author Professor Eamonn Kelly, University of Bristol.
JPET approves PN6047
In collaboration with our research partners at the University of Bristol, we have had a manuscript detailing the results of our preclinical studies of PN6047 accepted for publication in the highly cited Journal of Experimental Pharmacology and Therapeutics (JPET), the official journal of the American Society for Pharmacology and Experimental Therapeutics (ASPET).
We are delighted to have this peer-reviewed validation of our candidate compound made available for the Biomedical community to read and digest and we are confident that it will reignite interest in the potential value of biased signalling delta opioid receptor agonists for the treatment of a variety of conditions including our key target of neuropathic pain and for others including migraine, anxiety and depression and chronic cough. Details of the article which will soon be available electronically in advance of the printed version are shown below:
Title: A novel G protein-biased agonist at the δ opioid receptor with analgesic efficacy in models of chronic pain.
First Author: Dr Alexandra Conibear (Research Associate, School of Physiology, Pharmacology & Neuroscience, University of Bristol) with Corresponding Author Professor Eamonn Kelly, University of Bristol.
Latest news
View all
Positive FDA feedback for PN6047
PharmNovo has received positive and constructive feedback from the FDA for its lead drug candidate, PN6047, a selective delta opioid receptor agonist aimed at treating peripheral neuropathy with allodynia. Following a successful pre-IND meeting in January 2025, the FDA provided valuable guidance on the Phase IIa study design and had no critical comments on the CMC or non-clinical data. This paves the way for IND submission by the end of 2025 and a Phase IIa clinical trial application in Europe (Spain, Poland, Czech Republic) by Q3 2025.
Read more
Pioneering approach to treat neuropathic pain
PharmNovo has recently published an article in MedNous, highlighting the pioneering approach to tackling neuropathic pain without the risks traditionally associated with opioids. The lead candidate, PN6047, targets the delta-opioid receptor – offering pain relief without addiction or sedation. Arrangements for a Phase II trial have now been completed, marking a crucial step toward a safer alternative for millions suffering from chronic pain. With the opioid crisis still a major concern, innovative, non-addictive treatments like PN6047 are more urgent than ever.
Read more
PharmNovo live at neurology theme event at RedEye
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read more
PharmNovo at the LSX Nordic Congress
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read more